amoxicillin + tetracycline + furazolidone + levofloxacin + vonoprazan fumarate + esomeprazole

This is a multi-drug combination therapy consisting of six active pharmaceutical ingredients: - **Amoxicillin** (a beta-lactam antibiotic) - **Tetracycline** (a tetracycline-class antibiotic) - **Furazolidone** (a nitrofuran antimicrobial agent) - **Levofloxacin** (a fluoroquinolone antibiotic) - **Vonoprazan fumarate** (a potassium-competitive acid blocker, P-CAB) - **Esomeprazole** (a proton pump inhibitor, PPI) Such combinations are not standard as a single marketed product but may be used in research or clinical settings for the eradication of *Helicobacter pylori* or refractory gastric infections. The antibiotics act by inhibiting bacterial cell wall synthesis, protein synthesis, and DNA replication through their respective mechanisms. Vonoprazan and esomeprazole both suppress gastric acid secretion via different mechanisms—vonoprazan by competitively blocking the potassium-binding site on H+/K+-ATPase and esomeprazole by irreversibly inhibiting the same enzyme[3][6][2]. This dual acid suppression may enhance eradication rates in resistant cases.